Table 1.
Screening strategies evaluated for each adherence analysis.
Table 2.
Screening characteristics for Deep-C (clinicaltrials.gov identifier, NCT01397747) sensitivity analyses using granular adenoma size and location data.
Fig 1.
Percent difference in predicted Life-Years Gained (LYG) per 1000 individuals by adherence rate for triennial multitarget stool DNA (mt-sDNA) versus annual Fecal Immunochemical Test (FIT) in individuals free of diagnosed colorectal cancer at age 40 and screened between ages 50–75 years.
White boxes indicate <10% difference between tests. Light gray boxes indicate ≥10% positive difference with mt-sDNA versus FIT. Dark gray boxes indicate ≥10% negative difference with mt-sDNA versus FIT. Outlined box indicates base-case imperfect adherence rates.
Fig 2.
A) Predicted life-years gained (LYG), B) CRC-related incidence and mortality reduction, and C) total stool tests and colonoscopies (COL) per 1000 individuals screened from ages 50–75 compared with no screening assuming perfect (100%) adherence rates to annual FIT, annual HSgFOBT, and triennial mt-sDNA or base-case imperfect adherence (40% FIT vs 34% HSgFOBT vs 70% mt-sDNA).
Fig 3.
Life-years gained for individuals 40 years of age with stool-based tests by A) number of colonoscopies assuming perfect (100%) adherence or B) base-case imperfect adherence rates (40% FIT vs 34% HSgFOBT vs 70% mt-sDNA) and by C) patient hours related to the screening process assuming perfect (100%) adherence or D) base-case imperfect adherence (40% FIT vs 34% HSgFOBT vs 70% mt-sDNA). Results shown are per 1000 individuals free of diagnosed colorectal cancer at age 40 and screened starting at age 45 or 50 and ending at age 75 or 80 receiving biennial or triennial mt-sDNA, annual or biennial FIT, and annual or biennial HSgFOBT. NE, near-efficient.
Fig 4.
Predicted Life-Years Gained (LYG) by total stool tests per 1000 individuals screened from ages 50–75 compared with no screening.
Individuals were randomly assigned numbers of multitarget stool DNA (mt-sDNA; max = 9 triennial tests during the screening window) or fecal immunochemical tests (FIT; max = 26 annual tests during the screening window). The line indicates equivalent LYG with up to 9 mt-sDNA tests.
Table 3.
Predicted outcomes per 1000 individuals screened from ages 50–75 compared with no screening.